The cost-effectiveness of wound-edge protection devices compared to standard care in reducing surgical site infection after laparotomy: an economic evaluation alongside the ROSSINI trial. by Gheorghe, Adrian et al.
Gheorghe, A; Roberts, TE; Pinkney, TD; Bartlett, DC; Morton, D;
Calvert, M; West Midlands Research Collaborative; ROSSINI Trial
Investigators (2014) The cost-effectiveness of wound-edge protection
devices compared to standard care in reducing surgical site infection
after laparotomy: an economic evaluation alongside the ROSSINI
trial. PLoS One, 9 (4). e95595. ISSN 1932-6203 DOI: 10.1371/jour-
nal.pone.0095595
Downloaded from: http://researchonline.lshtm.ac.uk/2006352/
DOI: 10.1371/journal.pone.0095595
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
The Cost-Effectiveness of Wound-Edge Protection
Devices Compared to Standard Care in Reducing Surgical
Site Infection after Laparotomy: An Economic Evaluation
alongside the ROSSINI Trial
Adrian Gheorghe1, Tracy E. Roberts2, Thomas D. Pinkney3,4, David C. Bartlett4, Dion Morton3,4,
Melanie Calvert1,4*, on behalf of the West Midlands Research Collaborative and the ROSSINI Trial
Investigators
1 Primary Care Clinical Sciences, University of Birmingham, Birmingham, United Kingdom, 2Health Economics Unit, University of Birmingham, Birmingham, United
Kingdom, 3Academic Department of Surgery, University of Birmingham, Birmingham, United Kingdom, 4West Midlands Research Collaborative, Birmingham, United
Kingdom
Abstract
Background: Wound-edge protection devices (WEPDs) have been used in surgery for more than 40 years to reduce surgical
site infection (SSI). No economic evaluation of WEPDs against any comparator has ever been conducted. The aim of the
paper was to assess whether WEPDs are cost-effective in reducing SSI compared to standard care alone in the United
Kingdom.
Methods and Findings: An economic evaluation was conducted alongside the ROSSINI trial. The study perspective was that
of the UK National Health Service and the time horizon was 30 days post-operatively. The study was conducted in 21 UK
hospitals. 760 patients undergoing laparotomy were randomised to either WEPD or standard care and 735 were included in
the primary analysis. The main economic outcome was cost-effectiveness based on incremental cost (£) per quality adjusted
life year (QALY) gained. Patients in the WEPD arm accessed health care worth £5,420 on average and gained 0.02131 QALYs,
compared to £5,130 and 0.02133 QALYs gained in the standard care arm. The WEPD strategy was more costly and equally
effective compared to standard care, but there was significant uncertainty around incremental costs and QALYs. The
findings were robust to a range of sensitivity analyses.
Conclusions: There is no evidence to suggest that WEPDs can be considered a cost effective device to reduce SSI. Their
continued use is a waste of limited health care resources.
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Introduction
Surgical site infection (SSI) is a common postoperative
complication, occurring in up to five percent (5%) of all patients
undergoing surgery and 30–40% of patients undergoing abdom-
inal surgery depending on the level of contamination [1,2].
Development of an SSI significantly impacts upon patient
mortality and morbidity as well as healthcare costs [3]. In the
United Kingdom (UK), hospital length of stay is typically doubled
and additional per-patient costs of up to £10,000 have been
estimated, the variability depending upon the type and site of
surgery and the severity of the infection [4,5].
Wound-edge protection devices (WEPDs) have been used for
more than forty years to reduce SSI by creating a physical barrier
between the abdominal wound edges and viscera, visceral
contents, contaminated instruments and gloves, thereby reducing
accumulation of endogenous and exogenous bacteria on the
wound edges. Evidence on the clinical effectiveness of WEPDs has
been unclear: two systematic reviews of randomised controlled
trials (RCTs) suggested that WEPD may be effective in the
reduction of SSI [6,7], although the quality of the including RCTs
was low. To date there is no published evidence on the cost
effectiveness of WEPDs.
The objective of the ROSSINI (Reduction of Surgical Site
Infection using a Novel Intervention) trial was to explore the
effectiveness and cost-effectiveness of WEPD in reducing SSI after
laparotomy. In this paper we report the results of the economic
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evaluation conducted alongside ROSSINI which compared the
relative cost-effectiveness of WEPD compared to standard care
from the perspective of the UK National Health Service (NHS).
The economic evaluation is reported in accordance with the
CHEERS Statement (Appendix S1).
Methods
The trial protocol (Protocol S1) and recruitment flow chart are
presented as supplementary information.
Ethics Statement
The trial protocol [8] was approved before the study began by
the National Research Ethics Service (09/H1204/91; North
Staffordshire Committee) and the research and development team
at each hospital. Written informed consent was obtained from all
patients before enrolment on paper forms approved by the
aforementioned ethics body. ROSSINI was registered with
controlled-trials.com (ISRCTN 40402832).
Study Design
The full report on the trial has been reported elsewhere [9].
Briefly, the trial was a prospective, multicentre, observer blinded,
randomised controlled trial with stratification according to
baseline infection risk. Randomisation was performed when the
patient was in the anaesthetic room immediately before surgery
using a centralised secure web system provided by the University
of Birmingham. Randomisation was stratified according to the
urgency of surgery, likelihood of opening a viscus, and likelihood
of creating a stoma, with the use of a minimisation procedure. The
trial was conducted between February 2010 and January 2012 at
21 NHS hospitals across the UK. The cost-effectiveness analysis
was pre-specified in the trial protocol [8]. The objective of the
economic evaluation was to explore the relative cost-effectiveness
of WEPD compared to standard care. Cost, resource use and
outcome data in terms of QALYs were collected prospectively for
both arms of the trial. Costs and QALYs for the WEPD
intervention are compared to results of the standard care arm
and incremental costs and incremental QALYs are calculated as
the difference in costs and QALYs, respectively, between the
WEPD arm and the standard care arm. When appropriate, the
incremental cost-effectiveness ratio (ICER) was calculated as the
ratio of incremental costs (£) to incremental effects (QALY). In
this case, the ICER (£/QALY) represents the cost of obtaining an
additional QALY when switching from standard care to WEPDs.
Setting and Perspective
The trial-based evaluation took a health care provider
perspective and thus considered only cost centres relevant for
the NHS and Personal Social Services. The intervention under
scrutiny was the use of a WEPD during surgery in addition to
standard care. The comparator was no WEPD use, i.e. standard
care alone. In order to enhance the generalisability of the trial, the
surgical teams were given the liberty to use retraction and SSI
prophylactic procedures of their choice. The time horizon was 30
days post-operatively, in accordance with SSI monitoring in the
English NHS [10]. Given the short time horizon, no discounting
was applied to either costs or outcomes.
Data Collection
Health outcomes, preference-based outcomes and resource use
data were collected from the participating sites using custom
designed paper-based case report forms (CRFs), which were
completed by patients or trial staff, as appropriate, at each site
then managed centrally at the Centre for Clinical Trials at the
University of Birmingham.
Health Utility
We recorded health-related quality of life using the EuroQol
EQ-5D questionnaire (the English three-level response version and
validated for use in the UK, Appendix S2), a standardised generic
preference based instrument that describes a patient’s health status
using a single index value [11]. We used EQ-5D in this study
because of its relevance for the UK policy makers, particularly the
National Institute for Health and Clinical Excellence (NICE) [12].
We administered the EQ-5D instrument to patients in ROSSINI
at baseline (prior to surgery) and on two occasions post-
operatively. We conducted the first assessment in clinic, after the
patient provided informed consent and before randomisation. We
performed the second assessment (5 to 7 days) on the hospital ward
if still inpatient or at discharge, as applicable. We performed the
third assessment (30 to 33 days) on the hospital ward if still
Table 1. ROSSINI trial: unit costs at 2011 value.
Resource Unit cost (£) Source
WEPD (intervention) 15 Manufacturer [13]
HOSPITAL CARE
Day on general ward 311 NHS Reference Costs 2010/2011 [14]
Day in ITU 1515 NHS Reference Costs 2007/2008* [15]
Day in HDU 856 NHS Reference Costs 2007/2008* [15]
PRIMARY CARE
GP visit 36 Curtis 2011 [16]
Practice nurse visit 13 Curtis 2011 [16]
District nurse visit 73 Curtis 2011 [16]
Outpatient clinic visit 101 NHS Reference Costs 2010/2011 [14]
Medication as appropriate British National Formulary 2011 [17]
*The costs for a day in Intensive Therapy Unit (ITU) and a day in High Dependency Unit (HDU) were not available in NHS Reference Costs 2010/2011. The last available
document where they were given explicitly was the 2007/2008 edition. For the purpose of this analysis, the 2007/2008 unit costs were updated to their 2011 value using
the appropriate Hospital and community health services (HCHS) pay and price inflation (Curtis 2011).
doi:10.1371/journal.pone.0095595.t001
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inpatient or, more often, in the outpatient clinic on the occasion of
the scheduled follow-up visit. Only the baseline and third
assessment (30 to 33 days) were used to calculate QALYs; the
5–7 days assessment was employed in the multiple imputation
algorithms for missing EQ-5D scores at the final assessment.
Resource Utilisation
We collected data on resource utilisation of health care
resources prospectively in both secondary and primary care
settings using the custom designed CRFs (Appendix S2). Hospital
utilisation items were completed by health care staff and primary
care utilisation items were completed by patients in clinic at the
30-day visit.
Unit Costs
Unit costs were valued in £ (2011 value). The cost of the
intervention (WEPD) was obtained from the manufacturer [13].
Inpatient care resource items were sourced from the NHS
Reference Costs data [14,15]. Primary care resource items were
sourced from the Personal Social Services Resource Unit (PSSRU)
Unit Costs and Social Care 2010–2011 [16]. Medication unit costs
were taken from the British National Formulary 2011 [17]. All
unit costs were average national costs. Consistent with the NHS
Table 2. ROSSINI trial: summary of resource use by treatment group, detailed.
Resource use item WEPD (n=369) Standard care (n =366) p-value
HOSPITAL CARE
Inpatient days
N 359 358
Mean (SD) 12.55 (15.46) 11.56 (11.68) 0.3350
SE 0.82 0.62
Median 9 9
Days in ITU 369 366
N 0.93 (3.12) 1.06 (5.46) 0.6913
Mean (SD) 0.16 0.28
SE 0 0
Median
Days in HDU
N 369 366
Mean (SD) 0.60 (1.67) 0.51 (1.03) 0.6396
SE 0.09 0.08
Median 0 0
PRIMARY CARE
GP visits
N 364 358
Mean (SD) 0.43 (0.81) 0.51 (1.03) 0.2474
SE 0.04 0.05
Median 0 0
District nurse visits
N 360 355
Mean (SD) 3.43 (7.24) 3.52 (6.94) 0.8644
SE 0.38 0.37
Median 0 0
Practice nurse visits
N 366 361
Mean (SD) 0.16 (0.70) 0.32 (1.21) 0.0355
SE 0.04 0.06
Median 0 0
Outpatient clinic visits
N 364 363
Mean (SD) 0.42 (1.09) 0.31 (0.71) 0.1205
SE 0.06 0.04
Median 0 0
doi:10.1371/journal.pone.0095595.t002
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perspective, only resource use affecting the NHS budget were
considered. Total resource costs were obtained by summation of
the individual resource costs for each category of resource item
accessed by trial patients. Individual resource costs were obtained
by multiplying the resource use by the corresponding unit costs.
Data Analysis
In the base-case analysis we included all the patients with
complete primary outcome data. Any missing cost and health
utility data, as well as patient-level characteristics, were imputed
using the multiple imputations using chained equations method
(MICE) (Appendix S3). The analysis included descriptive statistics
for the resource use items, resource costs (both at aggregate and
individual level) and EQ-5D scores. QALYs were calculated by
multiplying the utility weight associated with each individual
health state and the time spent in that health state. QALYs were
calculated based on the baseline and 30-day EQ-5D assessments
and were adjusted for baseline utility [18].
The average differences in costs and outcomes, as well as the
95% confidence intervals around the point estimates, were
calculated using bias-corrected and accelerated (BCa) non-
parametric bootstrap with 1,000 replications [19]. The resulting
incremental costs and effects were plotted on the cost-effectiveness
plane, a visual decision-aiding tool representing the incremental
costs and effects of the intervention under evaluation relative to the
next best option [20]. Cost-effectiveness acceptability curves
(CEACs) were plotted, indicating the probability of each of the
two alternatives to be cost-effective at varying thresholds of the
decision makers’ willingness to pay for an additional unit of
outcome [21].
Table 3. ROSSINI trial: summary of missing data, by treatment group.
Missing data item Missing observations (% of trial arm)
WEPD (n=369) Standard care (n=366)
Trial arm differences
(p-value)
HOSPITAL CARE
Inpatient days 10 (2.7%) 8 (2.2%) 0.64
PRIMARY CARE
GP visits 5 (1.4%) 8 (2.2%) 0.39
Practice nurse visits 3 (0.8%) 5 (1.4%) 0.47
District nurse visits 9 (2.4%) 11 (3%) 0.63
Outpatient clinic visits 5 (1.4%) 3 (0.8%) 0.48
HEALTH UTILITY
EQ-5D data, any time point 51 (13.8%) 53 (14.5%) 0.79
doi:10.1371/journal.pone.0095595.t003
Table 4. Costs and health utilities in the ROSSINI trial, base-case analysis.
Variable WEPD (n=369) Standard care (n =366)
Costs (£), mean(SE)
Total cost 5420 (246) 5130 (234)
Intervention cost (WEPD) 15 n/a
Cost of inpatient care 5089 (247) 4812 (234)
General surgical ward 3638 (128) 3460 (122)
Intensive therapy unit 1123 (197) 1053 (186)
High dependency unit 329 (47) 299 (43)
Cost of primary care 316 (29) 318 (29)
GP visits 16 (2) 19 (2)
Practice nurse visits 2 (0.5) 4 (1)
District nurse visits 252 (27) 261 (28)
Outpatient clinic visits 44 (6) 33 (4)
Medication 1 (0.2) 1 (0.3)
Health-related quality of life, mean (SE)
QALY 0.0213 (0.0014) 0.0213 (0.0014)
EQ-5D score at baseline 0.751 (0.016) 0.752 (0.016)
EQ-5D score at 30 days 0.683 (0.016) 0.684 (0.016)
Note: Standard errors (SE) were calculated assuming a Gamma distribution for costs and a normal distribution for EQ-5D scores and QALYs.
doi:10.1371/journal.pone.0095595.t004
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Sensitivity analyses were performed to check the robustness of
cost-effectiveness findings, as follows: a complete case analysis
based on trial subjects with complete primary outcome, cost and
EQ-5D data (n = 532); and adjusted analyses for both base-case
and complete case scenarios, where differences between the trial’s
arms were investigated using generalized linear models. Total costs
and EQ-5D scores were regressed against the following pre-
specified covariates: intervention group, baseline utility (only for
adjusting incremental QALYs), plan to create a stoma, plan to
create a viscus (defined as any internal organ), elective/emergency
surgery, age, body mass index, diabetes, current smoking status
and SSI. The total cost and QALY values were regressed against
the variables above using generalised linear models with an
identity link [22]. A gamma distribution was assumed for costs and
a normal distribution was assumed for QALYs. The analyses were
performed using SAS 9.2 [23] and R 2.15.3 software [24].
Results
ROSSINI randomised 760 patients undergoing open abdom-
inal surgery between the use of WEPD during and standard care.
735 patients were included in the primary analysis, of which 369
patients received the intervention and 366 patients received
standard care. There was no evidence of benefit for WEPDs in
terms of SSI reduction (OR 0.97; 95% CI 0.69 to 1.36) or hospital
length of stay [25]. In total 20 patients died within 30 days of
surgery: 12 in the control group and eight in the intervention
group. For those patients who died within 30 days of surgery we
carried forward the last available wound assessment, unless no
information was available in which case they were treated as lost to
follow-up.
Table 1 presents the unit costs which informed the cost
calculations. Health care utilisation data by ROSSINI patients are
presented in Table 2. There is no apparent difference between the
two treatment groups for neither secondary care nor primary care
services. The only exception is the number of practice nurse visits:
patients in the standard care arm reported twice as many practice
nurse contacts than WEPD patients. When resource utilisation was
aggregated as nurse visits, there were no significant differences
between the two arms (Table S1).
Despite very low levels of missing data for the primary outcome,
the amount of missing data for resource utilisation and health
utility was somewhat higher (Table 3). EQ-5D scores at 30 days
post-operatively were not available for 14% of patients, while
hospital and primary care data were unavailable cumulatively for
less than 10% of patients (6.66%). Overall, 20.4% of patients had
incomplete observations in terms of resource use or EQ-5D data.
However, there was no imbalance between the two arms with
respect to the levels of missing data.
Cost-effectiveness
The base-case analysis used information from all patients with
complete primary outcome data (n = 735). The results of the
multiple imputation process are presented in Appendix S3.
Patients in the WEPD arm accessed health care worth £5,420
on average, compared to £5,130 for patients in the standard care
arm (Table 4). The use of the WEPD was associated with 0.02131
QALYs, compared to 0.02133 QALYs in the control group.
Overall, the WEPD strategy was on average £290 more costly
(95%CI -£372 to £948) and 0.00002 QALYs (95%CI-0.0018 to
0.0017) less beneficial than standard care, thus suggesting that
WEPD was technically dominated by standard care.
The cost-effectiveness plane (Figure 1) shows that both
incremental cost and incremental QALY estimates are associated
with considerable uncertainty. The cost-effectiveness acceptability
curves (CEACs) communicate the probability for an intervention
to be cost-effective for a range of willingness-to-pay thresholds (£/
Figure 1. ROSSINI trial economic evaluation: cost-effectiveness plane for the base-case analysis.
doi:10.1371/journal.pone.0095595.g001
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QALY). CEACs suggest that the WEPD is less than 30% likely to
be cost-effective in all analyses for the willingness-to-pay threshold
range of £20,000 to £30,000 recommended by NICE (Figure 2).
Sensitivity Analysis
The results of the regression adjusted analyses were similar to
the unadjusted results: in the base-case analysis, the incremental
cost increased from £290 to £311, while the QALY gain
increased from 20.00002 to 0.00018 (Table 5). The resulting
ICER is in excess of £1.7 million/QALY and, thus, much higher
than the threshold recommended by NICE. In the unadjusted
complete case scenario the ICER was £740,000/QALY; after
regression adjustment the WEPD became more costly and less
effective than standard care (Table 5).
Discussion
Summary of Findings
The WEPD intervention was associated with higher costs and
practically no QALY gains compared to standard care in the base-
case analysis; the confidence intervals for both incremental costs
and incremental QALYs show the extent of the uncertainty in the
findings (Figure 1). Within the willingness-to-pay interval recom-
mended by NICE [12], WEPDs were less than 30% likely to be
cost-effective compared to standard care in all analyses (Figure 2).
The result was robust to a range of sensitivity analyses. As such,
WEPDs are unlikely to be cost-effective compared to standard care
and their use cannot be recommended.
Although resource utilisation was comparable across the two
trial arms, patients in the standard care arm appear to have
received more practice nurse visits than intervention arm patients.
We believe this difference may be due to mis-classification of
patient reported visits on the trial case report forms (Appendix S2).
A sensitivity analysis is presented in Table S1: when nurse and
primary care contacts are aggregated, demonstrated that there is
no significant difference between the two arms. This does not
affect the cost-effectiveness findings.
Strengths and Limitations
To our knowledge, this study is the first economic evaluation of
WEPDs against any comparator and in any setting. It was an
integral part of the largest multi-centre RCT to date that
investigated the benefits of WEPDs. A wide range of sensitivity
analyses confirmed the robustness of base-case findings.
There are also several limitations. First, the choice of time
horizon may be subject to debate. The 30-day time horizon was
determined by the ROSSINI primary outcome i.e. the occurrence
of SSI within 30 days post-operatively, in line with the
international guidelines on SSI diagnosis [10,26]. A 30-day time
horizon was also adopted in other decision models which
evaluated interventions reducing SSI [27].
A further limitation refers to the complexity of SSI manage-
ment, especially in primary care. NICE clinical guidelines on SSI
care provide evidence that the weekly cost of wound dressings can
be up to £100, depending on the type of wound and the type of
dressing [28]. However, district nurses are the health care
professional most likely to apply the wound dressings in a primary
care setting and ROSSINI arms were more than comparable
regarding the number of district nurse visits, which reduces the
potential effect of not costing wound dressings (Table 2).
The uncertainty around the point estimates of incremental costs
and QALYs, reflected in the width of the confidence intervals, is
considerable. However, it is very unlikely that the ROSSINI trial
was underpowered: the pre-specified sample size in the statistical
analysis plan (n= 750), based on the best available evidence to
date, assumed a 50% reduction in SSI and a 12% SSI rate in the
study population. This suggests there may be a large amount of
variability in the cost and QALY gains associated with the use of
the WEPD. In support of this hypothesis, the primary outcome
Figure 2. ROSSINI trial economic evaluation: comparison of
cost-effectiveness acceptability curves across the analysed
scenarios. Legend: MI - Base-case analysis; CC - complete case analysis.
doi:10.1371/journal.pone.0095595.g002
Table 5. ROSSINI trial economic evaluation: summary of incremental costs and incremental QALYs across the analysed scenarios.
Scenario Variable
Mean difference
(WEPD – standard care) 95% BCa CI ICER
Base-case unadjusted Total cost (£) 290 2372 to 949 WEPD is dominated
QALY 20.00002 20.0018 to 0.0017
Base-case adjusted Total cost (£) 311 2273 to 1012 1,712 k/QALY
QALY 0.0002 20.0015 to 0.0019
Complete case unadjusted Total cost (£) 237 2407 to 892 740 k/QALY
QALY 0.0003 20.0023 to 0.0016
Complete case adjusted Total cost (£) 369 2214 to 976 WEPD is dominated
QALY 20.0001 20.0022 to 0.0019
doi:10.1371/journal.pone.0095595.t005
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also exhibited considerable uncertainty (OR 0.97, 95% CI 0.69 to
1.36).
Relation to other Studies
We have no knowledge of economic evaluations of WEPDs, but
there are published data on SSI costs. The most recent study on
the costs SSI care in a primary setting in the UK collected data on
29 SSI patients following colorectal surgery and found that
primary care costs amount to about 15% of total SSI costs (on
average £1,563 out of £10,523 per SSI patient), thus suggesting
that the largest part of the SSI cost burden comes from inpatient
care [5]. This is compatible with ROSSINI findings: primary care
cost accounted for less than 10% of total costs (Table 4). However,
Tanner et al. reported total and average resource use and costs,
respectively, without any mention of the variability around these
quantities. Variability is an important aspect, as illustrated in the
older study of Davey et al. [29]: out of seven patients with a SSI in
primary care, one patient alone received 57 district nurse visits,
another patient received two visits and the rest no visit at all.
Conclusion
The ROSSINI trial has shown WEPDs to be neither effective
nor cost-effective in reducing SSI compared to standard care. This
contradicts previous evidence, which suggested that WEPDs may
be effective. ROSSINI is the largest and most robust trial
investigating WEPDs to date and the first to have a pre-specified
integral economic evaluation. WEPDs have been used to date at
the surgeons’ discretion in the NHS to reduce SSI but there are no
official data on the WEPD utilisation and, as such, the current
NHS spending on WEPDs cannot be estimated. Our analyses
suggest that the use of WEPDs for SSI reduction cannot be
justified and should be discontinued.
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